Drugs / CSJ148
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03369912 | Oct 2018 → Nov 2022 | cytomegalovirus infection | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02268526 | Jun 2015 → Dec 2016 | cytomegalovirus infection | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSJ148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03369912 ↗ |
| Route | Intravenous | “CSJ148 IV q 4weeks” NCT02268526 ↗ |